Modern therapies used in the treatment of obesity, such as dual Glucagon-like peptide-1/GLP-1 and Gastric inhibitory polypeptide/GIP analogs (tirzepatide), have been shown to reduce the severity of obstructive sleep apnea symptoms, thereby indirectly improving respiratory function in these patients [28]. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.